JLE

European Journal of Dermatology

MENU

Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study Volume 32, issue 1, January-February 2022

Figures


  • Figure 1.
Authors
1 Dermatologic Clinic, University of Turin Medical School, Turin, Italy
2 Dermatology Unit, University of Campania, Naples, Italy
3 Oncological Dermatology and Skin Tumor Prevention Unit, Dermatological Hospital “San Gallicano”, Rome, Italy
4 Dermatology, IRCCS of Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
5 Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy
6 Polistudium SRL, Milan, Italy
7 Dermatologic Clinic, University of Genova, Genova, Italy

Adverse skin effects of antineoplastic therapies can reduce compliance, lead to skin complications and be associated with major psychological impact [1]. Xerosis cutis has been associated with targeted therapies, such as BRAFMEK inhibitors used in the treatment of metastatic melanoma (MM) [2].However, data on this topic are scant. In pivotal trials, xerosis cutis was reported as an adverse event in up to 16% of patients on these agents and up to 23% of those on MEK inhibitors only [3-6]. Xerosis [...]